Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

This December, Amgen received a second state incentive to expand its Holly Springs operations by adding another drug ...

Amgen (Nasdaq: AMGN) has completed construction of a $550 million drug manufacturing facility in the Wake County town.

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

Citi lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, the ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

The European Commission (EC) has approved Blincyto (blinatumomab) monotherapy as part of consolidation therapy for the treatment of adults with newly-diagnosed Philadelphia chromosome-negative ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...